HCW Biologics’ Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer
Globe Newswire•06/11/2026•11:00 ET
2
Key Highlights
- ➤HCW11-040 abstract ranked among SITC’s Top 150 of 1,200 submissions
- ➤HCW11-040 matched pembrolizumab’s PD1-PDL1 blocking activity in preclinical studies
- ➤HCW11-040 outperformed pembrolizumab rejuvenating exhausted T cells against cancer cells
- ➤HCW11-050 showed stronger anti-solid-tumor activity than checkpoint inhibitors in cold tumors
Designated as one of the Top 150 abstracts submitted for the 41(st) Annual Meeting of the Society for Immunotherapy of Cancer
HCW11-040 is a first-in-class, second-generation, tetravalent pembrolizumab (Keytruda®) based immune checkpoint inhibitor, built with Company’s proprietary non-Fc TRBC platform
Get started
Create a free account to read the full story.